Biophytis S.A. (ALBPS.PA)

0.6000 -0.0500 (-7.69%) 收市：05:08PM CEST

Biophytis S.A.

Sorbonne University
Bâtiment A 4ème étage 4 place Jussieu Cedex 05
Paris 75005
France
33 1 44 27 23 00
https://www.biophytis.com

版塊: Healthcare
行業: Biotechnology
全職員工: 22

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Stanislas Veillet Ph.D.	Chairman of the Board & CEO	349k	無	1965
Mr. Nicolas Fellmann	Chief Financial Officer	無	無	1968
Mr. Waly Dioh Ph.D.	Chief Clinical Operating Officer	無	無	1969
Dr. Pierre J. Dilda Ph.D.	Chief Scientific Officer	無	無	1970
Dr. Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	無	無	1946
Dr. Rob van Maanen FFPM, M.B.A., M.D.	Chief Medical Officer	無	無	1971
Mr. Edouard Bieth	Chief Business Officer	無	無	1980
Ms. Chiara Baccelli	Chief Pharmaceutical Operations Officer & Quality Assurance Director	無	無	無
Ms. _ Teylan	Financial Controller	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

公司管治

截至 無 止，Biophytis S.A. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。